Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice.

Morimoto, Hideto; Morioka, Hiroki; Imakiire, Atsushi; Yamamoto, Ryuji; Hirato, Tohru; Sonoda, Hiroyuki; Minami, Kohtaro.

Morimoto H; Research Division, JCR Pharmaceuticals, 2-2-9 Murotani, Nishi-ku, Kobe 651-2241, Japan.
Morioka H; Research Division, JCR Pharmaceuticals, 2-2-9 Murotani, Nishi-ku, Kobe 651-2241, Japan.
Imakiire A; Research Division, JCR Pharmaceuticals, 2-2-9 Murotani, Nishi-ku, Kobe 651-2241, Japan.
Yamamoto R; Research Division, JCR Pharmaceuticals, 2-2-9 Murotani, Nishi-ku, Kobe 651-2241, Japan.
Hirato T; Research Division, JCR Pharmaceuticals, 2-2-9 Murotani, Nishi-ku, Kobe 651-2241, Japan.
Sonoda H; Research Division, JCR Pharmaceuticals, 2-2-9 Murotani, Nishi-ku, Kobe 651-2241, Japan.
Minami K; Research Division, JCR Pharmaceuticals, 2-2-9 Murotani, Nishi-ku, Kobe 651-2241, Japan.

Mol Ther Methods Clin Dev ; 25: 534-544, 2022 Jun 09.

Article en En | MEDLINE | ID: mdl-35662814